• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Association Between DPP-4 Inhibitors and COVID-19-Related Outcomes Among Patients With Type 2 Diabetes.

作者信息

Noh Yunha, Oh In-Sun, Jeong Han Eol, Filion Kristian B, Yu Oriana Hoi Yun, Shin Ju-Young

机构信息

School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.

Departments of Medicine and of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.

出版信息

Diabetes Care. 2021 Apr;44(4):e64-e66. doi: 10.2337/dc20-1824. Epub 2021 Feb 5.

DOI:10.2337/dc20-1824
PMID:33547204
Abstract
摘要

相似文献

1
Association Between DPP-4 Inhibitors and COVID-19-Related Outcomes Among Patients With Type 2 Diabetes.2型糖尿病患者中DPP-4抑制剂与COVID-19相关结局的关联
Diabetes Care. 2021 Apr;44(4):e64-e66. doi: 10.2337/dc20-1824. Epub 2021 Feb 5.
2
Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.二肽基肽酶 4 抑制剂的使用与糖尿病患者大疱性类天疱疮风险的关联。
JAMA Dermatol. 2019 Feb 1;155(2):172-177. doi: 10.1001/jamadermatol.2018.4556.
3
Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.糖尿病患者中疱疹样天疱疮与二肽基肽酶-4 抑制剂的关联：评估新型药物的风险并描述患者特征。
JAMA Dermatol. 2018 Oct 1;154(10):1152-1158. doi: 10.1001/jamadermatol.2018.2352.
4
Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing.二肽基肽酶4抑制剂在老年2型糖尿病管理中的有效性和安全性：一项系统评价及减少不适当处方的建议制定
BMC Geriatr. 2017 Oct 16;17(Suppl 1):226. doi: 10.1186/s12877-017-0571-8.
5
Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.降糖治疗与 2 型糖尿病合并新发恶性肿瘤患者肿瘤转移的相关性。
Int J Cancer. 2019 Apr 1;144(7):1530-1539. doi: 10.1002/ijc.31870. Epub 2018 Dec 16.
6
Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis.二肽基肽酶4（DPP-4）抑制剂与2型糖尿病（T2DM）患者的心血管结局：一项系统评价和荟萃分析。
BMC Pharmacol Toxicol. 2019 Mar 4;20(1):15. doi: 10.1186/s40360-019-0293-y.
7
Complementary glucagonostatic and insulinotropic effects of DPP-4 inhibitors in the glucose-lowering action in Japanese patients with type 2 diabetes.二肽基肽酶-4抑制剂在日本2型糖尿病患者降糖作用中的胰高血糖素抑制和促胰岛素分泌协同效应。
Diabetol Int. 2015 Jul 11;7(2):133-140. doi: 10.1007/s13340-015-0219-x. eCollection 2016 Jun.
8
Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.二肽基肽酶-4抑制剂治疗2型糖尿病的成本效益
Pharmacoeconomics. 2015 Jun;33(6):581-97. doi: 10.1007/s40273-015-0266-y.
9
Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.二肽基肽酶-4 抑制剂与无心血管或肾脏疾病的 2 型糖尿病患者的心血管事件。
PLoS One. 2020 Oct 15;15(10):e0240141. doi: 10.1371/journal.pone.0240141. eCollection 2020.
10
Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study.2型糖尿病患者中DPP-4抑制剂与格列美脲心血管结局的比较安全性：一项回顾性队列研究。
Medicine (Baltimore). 2017 Jun;96(25):e7213. doi: 10.1097/MD.0000000000007213.

引用本文的文献

1
The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies.抗高血糖药物对 COVID-19 的影响：来自观察性研究的荟萃分析和系统评价。
Ther Innov Regul Sci. 2024 Jul;58(4):773-787. doi: 10.1007/s43441-024-00633-6. Epub 2024 Apr 29.
2
Preventative and therapeutic potential of animal milk components against COVID-19: A comprehensive review.动物乳成分对2019冠状病毒病的预防和治疗潜力：一项综述
Food Sci Nutr. 2023 Mar 23;11(6):2547-2579. doi: 10.1002/fsn3.3314. eCollection 2023 Jun.
3
Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis.
糖尿病合并 COVID-19 患者的非胰岛素类降糖药物：系统评价和荟萃分析。
J Diabetes. 2023 Feb;15(2):86-96. doi: 10.1111/1753-0407.13359. Epub 2023 Jan 23.
4
Reply to Firneisz: "Rebound increase in circulating dipeptidyl peptidase-4 (DPP4) enzyme activity after acute Covid-19".回复菲尔内伊斯：“新冠病毒急性感染后循环二肽基肽酶-4（DPP4）酶活性的反弹增加”
Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2220329120. doi: 10.1073/pnas.2220329120. Epub 2023 Jan 9.
5
Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control.用于治疗新冠肺炎的二肽基肽酶4抑制剂：超越血糖控制。
World J Virol. 2022 Nov 25;11(6):399-410. doi: 10.5501/wjv.v11.i6.399.
6
The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus.二肽基肽酶-4抑制剂在2型糖尿病患者新冠病毒感染预后中的作用
J Res Med Sci. 2022 Aug 27;27:62. doi: 10.4103/jrms.jrms_71_22. eCollection 2022.
7
Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?西他列汀对 SARS-CoV-2 感染有效吗：虚假还是真实的预言？
Inflammopharmacology. 2022 Dec;30(6):2411-2415. doi: 10.1007/s10787-022-01078-9. Epub 2022 Sep 30.
8
Novel hit of DPP-4Is as promising antihyperglycemic agents with dual antioxidant/anti-inflammatory effects for type 2 diabetes with/without COVID-19.新型 DPP-4I 作为有前景的抗高血糖药物，具有抗氧化/抗炎双重作用，可用于治疗有/无 COVID-19 的 2 型糖尿病。
Bioorg Chem. 2022 Nov;128:106092. doi: 10.1016/j.bioorg.2022.106092. Epub 2022 Aug 10.
9
Plasma metabolome and cytokine profile reveal glycylproline modulating antibody fading in convalescent COVID-19 patients.血浆代谢组和细胞因子谱揭示甘氨酰脯氨酸调节抗体衰减在恢复期 COVID-19 患者中。
Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2117089119. doi: 10.1073/pnas.2117089119. Epub 2022 Aug 9.
10
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.糖尿病 COVID-19 患者的降糖药物与临床结局的相关性：贝叶斯网状 Meta 分析。
Front Endocrinol (Lausanne). 2022 May 27;13:895458. doi: 10.3389/fendo.2022.895458. eCollection 2022.